Literature DB >> 19280465

Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.

Stephanie E Combs1, Jessica Bohl, Thilo Elsasser, Klaus-Josef Weber, Daniela Schulz-Ertner, Jurgen Debus, Wilma K Weyrather.   

Abstract

PURPOSE: To investigate the cytotoxic effect of high linear-energy transfer (LET) carbon irradiation on glioblastoma cells lines in combination with temozolomide (TMZ). METHODS AND MATERIALS: The cell lines U87-MG expressing wild-type p53 and LN229 expressing both mutant and wild-type p53 were irradiated with monoenergetic carbon ion beams (LET 172 keV/microm) or an extended Bragg peak (LET 103 keV/microm) after treatment with 10 microM or 20 microM TMZ. Cytotoxicity was measured by a clonogenic survival assay, and cell growth as well as cell cycle progression, were examined.
RESULTS: The p53 mutant was more sensitive to X-ray irradiation than the p53 wild type cell line, which was also expressed in a shorter G2 block. High LET carbon ions show an increased biological effectiveness in both cell lines, which is consistent with the predictive calculations by the Local Effect Model (LEM) introduced by Scholz et al. The cell line LN229 was more sensitive to TMZ treatment than the U87MG cell line expressing wild-type p53 only. The combination of TMZ and irradiation showed an additive effect in both cell lines.
CONCLUSION: High LET carbon ion irradiation is significantly more effective for glioblastoma cell lines compared to photon irradiation. An additional treatment with TMZ may offer a great chance especially for several tumor types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280465     DOI: 10.1080/09553000802641151

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  32 in total

1.  [Translational uroradio-oncology].

Authors:  S E Combs; J Debus
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

2.  "Broadbeam" irradiation of mammalian cells using a vertical microbeam facility.

Authors:  J C G Jeynes; M J Merchant; L Barazzuol; M Barry; D Guest; V V Palitsin; G W Grime; I D C Tullis; P R Barber; B Vojnovic; K J Kirkby
Journal:  Radiat Environ Biophys       Date:  2013-08-21       Impact factor: 1.925

3.  Evaluation of radiation-related invasion in primary patient-derived glioma cells and validation with established cell lines: impact of different radiation qualities with differing LET.

Authors:  M Wank; D Schilling; J Reindl; B Meyer; J Gempt; S Motov; F Alexander; J J Wilkens; J Schlegel; T E Schmid; S E Combs
Journal:  J Neurooncol       Date:  2018-06-08       Impact factor: 4.130

4.  The effect of silibinin in enhancing toxicity of temozolomide and etoposide in p53 and PTEN-mutated resistant glioma cell lines.

Authors:  Rashid Elhag; Elizabeth A Mazzio; Karam F A Soliman
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

Review 5.  Carbon ion radiotherapy in the treatment of gliomas: a review.

Authors:  Timothy D Malouff; Jennifer L Peterson; Anita Mahajan; Daniel M Trifiletti
Journal:  J Neurooncol       Date:  2019-09-30       Impact factor: 4.130

6.  Integrin-based meningioma cell migration is promoted by photon but not by carbon-ion irradiation.

Authors:  Florian Simon; Jan-Oliver Dittmar; Stephan Brons; Lena Orschiedt; Steffi Urbschat; Klaus-Josef Weber; Jürgen Debus; Stephanie E Combs; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2014-12-02       Impact factor: 3.621

Review 7.  Recent advancements in multimodality treatment of gliomas.

Authors:  Mersiha Hadziahmetovic; Katsuyuki Shirai; Arnab Chakravarti
Journal:  Future Oncol       Date:  2011-10       Impact factor: 3.404

8.  Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Anna Nikoghosyan; Renate Haselmann; Andreas Unterberg; Wolfgang Wick; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-09-06       Impact factor: 4.430

9.  Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.

Authors:  Stephanie E Combs; Lutz Edler; Iris Burkholder; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Andreas Unterberg; Wolfgang Wick; Jürgen Debus; Renate Haselmann
Journal:  BMC Cancer       Date:  2010-11-09       Impact factor: 4.430

Review 10.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.